Otsuka Corporation (TYO: 4768)

Japan flag Japan · Delayed Price · Currency is JPY
3,659.00
+9.00 (0.25%)
Dec 19, 2024, 3:45 PM JST
22.70%
Market Cap 1.37T
Revenue (ttm) 1.06T
Net Income (ttm) 50.94B
Shares Out 379.20M
EPS (ttm) 134.35
PE Ratio 26.81
Forward PE 23.97
Dividend 70.00 (1.94%)
Ex-Dividend Date Dec 27, 2024
Volume 490,000
Open 3,612.00
Previous Close 3,650.00
Day's Range 3,612.00 - 3,681.00
52-Week Range 2,835.00 - 3,789.00
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date Jan 31, 2025

About Otsuka

Otsuka Corporation, together with its subsidiaries, operates as an information technology (IT) platformer in Japan. It operates through System Integration Business, and Service and Support Business segments. The System Integration Business segment offers management systems and collaborative software, such as ERP packages and groupware to cover a range of specialized fields, including CAD and web technologies; and software, hardware, intranet, and security products for the construction and expansion of computer networks, as well as intermediary ... [Read more]

Industry Technology Distributors
Sector Technology
Founded 1961
Employees 9,421
Stock Exchange Tokyo Stock Exchange
Ticker Symbol 4768
Full Company Profile

Financial Performance

In 2023, Otsuka's revenue was 977.37 billion, an increase of 13.51% compared to the previous year's 861.02 billion. Earnings were 47.45 billion, an increase of 18.55%.

Financial Statements

News

Otsuka submits NDA in Japan for the treatment of hypercholesterolemia

Esperion's partner Otsuka submits New Drug Application for bempedoic acid in Japan for hypercholesterolemia treatment.Expansion of market potential.

25 days ago - Seeking Alpha

Otsuka Is Said to Weigh Sale of Stake in Medical Device Maker MicroPort Scientific

Otsuka Holdings Co. is considering options for its holding in Hong Kong-listed MicroPort Scientific Corp., including selling its stake in the medical device maker, according to people familiar with th...

2 months ago - BNN Bloomberg

Citi maintains ‘Sell’ rating on Lupin, sets target at Rs 1,700

Citi has reiterated its “Sell” recommendation for Lupin, with a target price of Rs 1,700 per share. This comes in light of recent developments regarding Lupin’s generic version of Jynarque. Key points...

3 months ago - Business Upturn